Although NAT2 is expressed in prostate epithelium and the liver [13], our results suggest that the expression of the NAT2 phenotype in the liver has greater metabolic influence on HAA carcinogens of prostate cancer than its expression in the prostate. This evidence concerns the gene NAT2 and prostate cancer.